These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18484596)

  • 1. High prevalence of triple-negative tumors in an urban cancer center.
    Lund MJ; Butler EN; Bumpers HL; Okoli J; Rizzo M; Hatchett N; Green VL; Brawley OW; Oprea-Ilies GM; Gabram SG
    Cancer; 2008 Aug; 113(3):608-15. PubMed ID: 18484596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
    McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
    Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.
    Giuliani S; Leonardi E; Aldovini D; Bernardi D; Pellegrini M; Soli F; Ferro A; Dalla Palma P; Decarli N; Barbareschi M
    Pathologica; 2012 Jun; 104(3):93-7. PubMed ID: 22931039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.
    Swede H; Gregorio DI; Tannenbaum SH; Brockmeyer JA; Ambrosone C; Wilson LL; Pensa MA; Gonsalves L; Stevens RG; Runowicz CD
    Clin Breast Cancer; 2011 Oct; 11(5):332-41. PubMed ID: 21729670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.
    Chollet-Hinton L; Olshan AF; Nichols HB; Anders CK; Lund JL; Allott EH; Bethea TN; Hong CC; Cohen SM; Khoury T; Zirpoli GR; Borges VF; Rosenberg LA; Bandera EV; Ambrosone CB; Palmer JR; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1722-1729. PubMed ID: 28903991
    [No Abstract]   [Full Text] [Related]  

  • 10. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
    Stead LA; Lash TL; Sobieraj JE; Chi DD; Westrup JL; Charlot M; Blanchard RA; Lee JC; King TC; Rosenberg CL
    Breast Cancer Res; 2009; 11(2):R18. PubMed ID: 19320967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 as a marker of prognosis in African-American women with breast cancer.
    Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
    Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
    BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study.
    Williams LA; Olshan AF; Tse CK; Bell ME; Troester MA
    Cancer Causes Control; 2016 Feb; 27(2):259-69. PubMed ID: 26705260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.